A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults

Document Details

Document Type
Pub Defense Publication
Publication Date
Jun 01, 2023
Source ID
10.1016/j.vaccine.2023.04.064

Entities

People

  • Allison August
  • Christine A Shaw
  • Conor Knightly
  • Honghong Zhou
  • Lori Panther
  • Peta-gay Jackson Booth
  • Scott C. Weaver
  • Stephan Bart
  • Trevor Brasel

Organizations

  • Defense Advanced Research Projects Agency
  • Moderna

Tags

Technology Areas

  • Biotechnology